Background There is a lack of information on the role of chronic use of hydroxychloroquine during the SARS-CoV-2 outbreak. Our aim was to compare the occurrence of COVID-19 between rheumatic disease patients on hydroxychloroquine with individuals from the same household not taking the drug during the first 8 weeks of community viral transmission in Brazil. Methods This baseline cross-sectional analysis is part of a 24-week observational multi-center study involving 22 Brazilian academic outpatient centers. All information regarding COVID-19 symptoms, epidemiological, clinical, and demographic data were recorded on a specific web-based platform using telephone calls from physicians and medical students. COVID-19 was defined according to the Brazilian Ministry of Health (BMH) criteria. Mann–Whitney, Chi-square and Exact Fisher tests were used for statistical analysis and two binary Final Logistic Regression Model by Wald test were developed using a backward-stepwise method for the presence of COVID-19. Results From March 29th to May 17st, 2020, a total of 10,443 participants were enrolled, including 5166 (53.9%) rheumatic disease patients, of whom 82.5% had systemic erythematosus lupus, 7.8% rheumatoid arthritis, 3.7% Sjögren’s syndrome and 0.8% systemic sclerosis. In total, 1822 (19.1%) participants reported flu symptoms within the 30 days prior to enrollment, of which 3.1% fulfilled the BMH criteria, but with no significant difference between rheumatic disease patients (4.03%) and controls (3.25%). After adjustments for multiple confounders, the main risk factor significantly associated with a COVID-19 diagnosis was lung disease (OR 1.63; 95% CI 1.03–2.58); and for rheumatic disease patients were diagnosis of systemic sclerosis (OR 2.8; 95% CI 1.19–6.63) and glucocorticoids above 10 mg/ day (OR 2.05; 95% CI 1.31–3.19). In addition, a recent influenza vaccination had a protective effect (OR 0.674; 95% CI 0.46–0.98). Conclusion Patients with rheumatic disease on hydroxychloroquine presented a similar occurrence of COVID-19 to household cohabitants, suggesting a lack of any protective role against SARS-CoV-2 infection. Trial registration Brazilian Registry of Clinical Trials (ReBEC; RBR – 9KTWX6).
【저자키워드】 COVID-19, Rheumatic diseases, Hydroxycloroquine, 【초록키워드】 Brazil, vaccination, Hydroxychloroquine, Influenza, SARS-COV-2 infection, Diagnosis, Lung disease, Symptom, risk factor, glucocorticoid, rheumatoid arthritis, outbreak, clinical, Patient, COVID-19 diagnosis, Model, Control, Community, Viral transmission, Systemic sclerosis, epidemiological, flu, registry, information, disease, COVID-19 symptoms, patients, protective effect, statistical analysis, Regression, criteria, Sjögren’s syndrome, Enrollment, 95% CI, no significant difference, individual, demographic data, cross-sectional analysis, web-based platform, confounders, participant, protective role, physician, Chi-square, Ministry of Health, systemic erythematosus lupus, Result, enrolled, defined, lack, significantly, reported, addition, were used, were recorded, baseline, Fisher test, occurrence of COVID-19, the SARS-CoV-2, use of hydroxychloroquine, Wald test, 【제목키워드】 Brazil, Patient, large cohort, rheumatic disease, chronic, PROTECT, use of hydroxychloroquine,